New and emerging drugs for the treatment of obesity.
10.5124/jkma.2015.58.5.452
- Author:
Eun ROH
1
;
Min Seon KIM
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. mskim@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Obesity;
Drug;
Development
- MeSH:
Anti-Obesity Agents;
Cardiovascular Diseases;
Cause of Death;
Comorbidity;
Life Style;
Liraglutide;
Mortality;
Obesity*;
Public Health;
Weight Loss
- From:Journal of the Korean Medical Association
2015;58(5):452-457
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Obesity has become a global public health problem. The importance of obesity is highlighted by the fact that obesity-related comorbidities, such as type 2 diabetes, cardiovascular disease, and cancer, are a leading cause of death in Westernized countries. As endorsement of lifestyle modifications has proven to be inadequate to combat obesity, pharmacological treatment has become more critical for weight reduction as well as for the treatment of obesity-related morbidity and mortality. However, safety issues dampened the success of the development of anti-obesity drugs, leaving orlistat as the single approved drug for long-term weight management until 2012, when two new anti-obesity drugs were approved by the FDA: lorcaserin and phentermine/topiramate. In 2014, another two drugs were approved by the US FDA for the treatment of obesity: naltrexone/bupropion and liraglutide. In this review, we describe the new FDA-approved anti-obesity drugs and briefly introduce other anti-obesity drugs still under development.
